Subject: [SpinLyme] NYT; Grassley: "When standing to profit..."
Date: Feb 27, 2008 6:44 PM
ARTICLE BELOW.
Okay, can we be clear on this now?
The www.ALDF.com (the Lyme cabal) was founded at New York Medical
College in 1990:
http://www.actionlyme.org/CONNOLLY_FISH_WEINSTEIN.htm
with the stated intention to profiteer off vector borne diseases test
kits and vaccines:
"The entrepreneurial trio are Durland Fish, Ph.D., former director of
the College's
Lyme Disease Center and now a research scientist at Yale; Gary P.
Wormser, M.D.,
still professor of medicine and pharmacology and chief of the Division
of Infectious
Diseases at the College; and John J. Connolly, Ed.D., former College
president and
current chairman of the board of the American Lyme Disease Foundation,
Inc., which
had its genesis on the Valhalla campus in 1990."
Kaiser-Permanente was and still is training MDs at New York Medical
College- which
provides the OPMC with their so-called experts in harassment cases:
http://www.actionlyme.org/OPMC_CORRUPTION.htm
The continued profiteering and conflicts of interest are about keeping
the lid on
the first crime: Redefining Lyme Disease as only an arthritis in a
knee to 1) suit
the false positive outcomes of LYMErix and ImmuLyme, and 2) deny
treatment for neurologic
Lyme, since Relapsing Fever is more expensive to treat that AIDS.
That was the fake Dearborn Conference:
http://www.actionlyme.org/CRYMEDISEASE_CHP3.htm
Gary Wormser and Allen Steere are on Baxter's payroll:
http://www.actionlyme.org/WORMSER_INSISTS_LYME_A_KNEE_DISEASE.htm
By maintaining the lie that the Dearborn testing criteria was
accurate:
http://www.actionlyme.org/CRYMEDISEASE_CHP3.htm
they intend to defend against personal lawsuits where they also state
that there
is no such thing as chronic Lyme, and that there is no such thing as
"seronegative
Lyme," when they themselves reported numerous times about treatment
failure,
and Gary Wormser himself demonstrated that the current testing for
Lyme misses 50/59
cases:
http://www.actionlyme.org/LYME_A_PERMANENT_BRAIN_INFECTION.htm
(that's the crooks own data)
http://www.actionlyme.org/HOW_RICO_WILL_BE_CHARGED.htm
(Wormser reports that he knows what primers to use when he REALLY
wants to find
Lyme disease and he assessed Steere's proposal for Dearborn and found
it only
detected 9/59 cases)
http://wwww.actionlyme.org/GARY_WORMSER_SUED.htm
Lyme Cryme is huger than any other medical crime and it is
international, and they
write bogus articles at New York Medical College and have imported
some defecting
Russians to publish nonsense from NYMC:
http://www.actionlyme.org/BOGUS_RUSSIAN_NYMC_ARTICLES.htm
Why aren't these Russian-NYMC weaponeers the authors of the ALDF's/
IDSociety's
"Lyme Disease" "guidelines?"
Because we might ask them, "What the hell do you *MEAN,* by reporting
that
'intracellular spirochetes are not intracellular?'"
LOL
Kathleen M. Dickson
23 Garden Street
Pawcatuck, CT 06379
http://www.nytimes.com/2008/02/27/business/27cnd-device.html?hp=&pagewanted=print
The New York Times
Printer Friendly Format Sponsored By
February 27, 2008
F.D.A. and Disk Maker Questioned
By REED ABELSON
A ranking member of the Senate Finance Committee has asked the Food
and Drug Administration
and the maker of an artificial spinal disk about potential financial
conflicts of
many of the doctors involved in the clinical research that led to
F.D.A. approval
of the device.
The financial relationships were the subject of a front-page New York
Times article
in late January. Doctors at about half the research centers involved
in the study
of the artificial disk, the Prodisc, had a direct financial interest
in the device's
success.
Prodisc, originally made and tested by an American company, is now
manufactured
by the Swiss manufacturer Synthes, whose United States headquarters
received a letter
of inquiry on late Tuesday from Charles E. Grassley of Iowa, the
ranking Republican
on the Senate Finance Committee. The F.D.A. received a letter from Mr.
Grassley
on Wednesday.
Citing what he described as suggestions of "a dangerous conflict of
interest," Mr.
Grassley's letters asked the F.D.A. and Synthes to provide accounts of
what the
company disclosed to regulators about the researchers before the
disk's approval
in 2006. Mr. Grassley also asked how the agency and company handle
potential conflicts
among clinical investigators.
"We will cooperate fully with the request of Senator Grassley," said a
spokesman
for Synthes. An F.D.A. spokeswoman said the agency did not comment on
pending requests
for information.
The inquiry is part of a broad look by Mr. Grassley and others in
Congress into
the close financial ties between physicians and the manufacturers of
drugs and devices.
Last year, Mr. Grassley introduced legislation that would require
corporations to
publicly disclose any money they give to doctors.
The legislation was co-sponsored by Senator Herb Kohl, the Wisconsin
Democrat who
is chairman of the Special Committee on Aging. Mr. Kohl held a hearing
on Wednesday
about the broad issue of physician conflicts of interest. Testimony
included executives
from two medical device makers, Zimmer Holdings and Stryker, that were
among manufacturers
that recently settled with the Justice Department over accusations
that they used
consulting agreements and other means to persuade doctors to back
their products.
An official from the Department of Health and Human Services'
inspector general's
office the testified at the Kohl hearing about the potential conflicts
and possible
illegal behavior of doctors who are investors in makers of devices
they use on patients
and recommend to other doctors.
In the matter under examination by Mr. Grassley, Prodisc was developed
by Spine
Solutions, a start-up device company that was later sold to Synthes. A
New York
investment firm, Viscogliosi Brothers, helped found Spine Solutions
and financed
the disk's development and research through a number of investment
funds in which
many of the clinical investigators were also investors.
"Clinical investigators play a critical part of the F.D.A. approval
process," Mr.
Grassley wrote in the letters to the F.D.A. and Synthes. "These
physicians are expected
to act objectively in testing the safety and effectiveness of the drug
or medical
device under consideration. But when they stand to profit from F.D.A.
approval of
the product they are testing, the investigator's objectivity is called
into question.
The New York Times brought to light just this type of situation in the
case of Prodisc,
an artificial disk."
In his letter to Synthes, Mr. Grassley asked the company to tell the
Finance Committee
what information it had disclosed to the F.D.A., to detail its
discussions with
Viscogliosi Brothers about the investigators' interests and to outline
the company's
"internal policies, guidelines and/or standards regarding clinical
investigators
and their potential conflicts of interests."The F.D.A. has said it is
looking into
whether adequate disclosures were made about the Prodisc researchers'
potential
financial conflicts. A spokeswoman for the agency said Wednesday she
did not have
any further information.
If the agency was aware of the financial relationships, Mr. Grassley
wrote, he wants
it to describe its reasoning about whether those relationships would
affect the
integrity of the Prodisc trial. "If F.D.A. found out the investment
interests did
not raise the serious questions about the study's integrity," he
wrote, "why not?"
Home
IGNORE KRAZY KATHLEEN'S OFF TOPIC GARBAGE SPAM DO YOURSELF A FAVOR AND
SCROLL ON BY